This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cancer in Slovenia 2016 Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2019.Cancer in Slovenia 2016 Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2019Search in Google Scholar
Zakotnik B, Zadnik Z, Žagar T, Primic Žakelj M, Ivanuš U, Jerman T, et al. Reaching sustainable oncology care via the National Cancer Control Program (NCCP). Ann Oncol 2019; 30(Suppl 5): v671-82. doi: 10.1093/annonc/mdz263ZakotnikBZadnikZŽagarTPrimicŽakelj MIvanušUJermanTet alReaching sustainable oncology care via the National Cancer Control Program (NCCP)Ann Oncol201930Suppl 5v6718210.1093/annonc/mdz263Open DOISearch in Google Scholar
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 1.2020. [cited 2020 Feb 28]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon_cancer.pdfNational Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancerVersion 1.2020. [cited 2020 Feb 28]. Available athttps://www.nccn.org/professionals/physician_gls/pdf/colon_cancer.pdfSearch in Google Scholar
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-422. doi: 10.1093/annonc/mdw235VanCutsem ECervantesAAdamRSobreroAVanKrieken JHAderkaDet alESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnn Oncol201627138642210.1093/annonc/mdw23527380959Open DOISearch in Google Scholar
Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 2019; 109: 70-83. doi: 10.1016/j.ejca.2018.12.019ModestDPPantSSartore-BianchiATreatment sequencing in metastatic colorectal cancerEur J Cancer2019109708310.1016/j.ejca.2018.12.01930690295Open DOISearch in Google Scholar
Patel JN, Fon MK, Jagosky M. Colorectal cancer biomarkers in the era of personalized medicine. J Pers Med 2019; 9(1). doi: 10.3390/jpm9010003PatelJNFonMKJagoskyMColorectal cancer biomarkers in the era of personalized medicineJ Pers Med20199110.3390/jpm9010003646311130646508Open DOISearch in Google Scholar
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21:1350-6. doi: 10.1038/nm.3967GuinneyJDienstmannRWangXde ReynièsASchlickerASonesonCet alThe consensus molecular subtypes of colorectal cancerNat Med2015211350610.1038/nm.3967463648726457759Open DOISearch in Google Scholar
Rebersek M, Mesti T, Boc M, Ocvirk J. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients. Radiol Oncol 2019; 53: 85-95. doi: 10.2478/raon-2019-0013RebersekMMestiTBocMOcvirkJMolecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patientsRadiol Oncol201953859510.2478/raon-2019-0013641102130840593Open DOISearch in Google Scholar
Afrasanie VA, Marinca MV, Alexa-Stratulat T, Păduraru M I, Adavidoaiei AM, Miron L, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician. Radiol Oncol 2019; 53: 265-74. doi: 10.2478/raon-2019-0033AfrasanieVAMarincaMVAlexa-StratulatTPăduraruM IAdavidoaieiAMMironLet alKRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinicianRadiol Oncol2019532657410.2478/raon-2019-0033676516031553708Open DOISearch in Google Scholar
Inamura K. Colorectal cancers: an update on their molecular pathology. Cancers 2018; 10: pii: E26. doi: 10.3390/cancers10010026InamuraKColorectal cancers: an update on their molecular pathologyCancers201810pii: E2610.3390/cancers10010026578937629361689Open DOISearch in Google Scholar
Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017; 17: 79-92. doi: 10.1038/nrc.2016.126DienstmannRVermeulenLGuinneyJKopetzSTejparSTaberneroJConsensus molecular subtypes and the evolution of precision medicine in colorectal cancerNat Rev Cancer201717799210.1038/nrc.2016.12628050011Open DOISearch in Google Scholar
Fontana E, Eason K, Cervantes A, Salazar, R, Sadanandam A. Context matters - consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol 2019; 30: 520-7. doi: 10.1093/annonc/mdz052FontanaEEasonKCervantesASalazarRSadanandamAContext matters - consensus molecular subtypes of colorectal cancer as biomarkers for clinical trialsAnn Oncol201930520710.1093/annonc/mdz052650362730796810Open DOISearch in Google Scholar
Thanki K, Nicholls ME, GajjarA, Senagore AJ, Qiu S, Szabo C, et al. Consensus molecular subtypes of colorectal cancer and their clinical implications. Int Biol Biomed J 2017; 3: 105-11. PMID: 28825047ThankiKNichollsMEGajjarASenagoreAJQiuSSzaboCet alConsensus molecular subtypes of colorectal cancer and their clinical implicationsInt Biol Biomed J2017310511PMID: 28825047Search in Google Scholar
Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res 2018; 24: 1062-72. doi: 10.1158/1078-0432.CCR-17-2484LoreeJMPereiraAALLamMWillauerANRaghavKDasariAet alClassifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypesClin Cancer Res20182410627210.1158/1078-0432.CCR-17-2484Open DOISearch in Google Scholar
Dienstmann R, Salazar R, Tabernero J. Molecular subtypes and the evolution on of treatment decisions in metastatic colorectal cancer. Am Soc Clin Oncol Educ Book 2018; 38: 231-8. doi: 10.1200/EDBK_200929DienstmannRSalazarRTaberneroJMolecular subtypes and the evolution on of treatment decisions in metastatic colorectal cancerAm Soc Clin Oncol Educ Book201838231810.1200/EDBK_200929Open DOISearch in Google Scholar
Kato S, Schwaederle MC, Fanta PT, Okamura R, Leichman L, Lippman SC, et al. Genomic assessment of blood- derived circulating tumor DNA in patients with colorectal cancers: Correlation with tissue sequencing, therapeutic response, and survival. JCO Precis Oncol 2019; 3: 1-25. doi: 10.1200/PO.18.00158KatoSSchwaederleMCFantaPTOkamuraRLeichmanLLippmanSCet alGenomic assessment of blood- derived circulating tumor DNA in patients with colorectal cancers: Correlation with tissue sequencing, therapeutic response, and survivalJCO Precis Oncol2019312510.1200/PO.18.00158Open DOISearch in Google Scholar
Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 2018; 29: 119-26. doi: 10.1093/annonc/mdx504SienaSSartore-BianchiAGarcia-CarboneroRKarthausMSmithDTaberneroJet alDynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancerAnn Oncol2018291192610.1093/annonc/mdx504Open DOISearch in Google Scholar
Lenz, HJ, Ou FS, Venook, AP, Hochster HS, Niedzwiecki D, Richard M, et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). J Clin Oncol 2019; 37: 1876-85. doi: 10.1200/JCO.18. 02258LenzHJOuFSVenookAPHochsterHSNiedzwieckiDRichardMet alImpact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance)J Clin Oncol20193718768510.1200/JCO.18.02258Open DOISearch in Google Scholar
Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol 2019; 20: e274-83. doi: 10.1016/S1470-2045(19)30172-XAderkaDStintzingSHeinemannVExplaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studiesLancet Oncol201920e2748310.1016/S1470-2045(19)30172-XOpen DOISearch in Google Scholar
Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol 2019; 30: 1796-803. doi: 10.1093/annonc/mdz387StintzingSWirapatiPLenzHJNeureiterDFischervon Weikersthal LDeckerTet alConsensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialAnn Oncol201930179680310.1093/annonc/mdz387692731631868905Open DOISearch in Google Scholar
Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 2019; 16: 690-704. doi: 10.1038/s41575-019-0209-8WongSHYuJGut microbiota in colorectal cancer: mechanisms of action and clinical applicationsNat Rev Gastroenterol Hepatol20191669070410.1038/s41575-019-0209-831554963Open DOISearch in Google Scholar
